More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at changes in circulating tumor cells (CTC) and the second to the onset of the use of opioid painkillers. Abstract #40 [...]
Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]
Some more good news for the advanced prostate cancer community was announced today. Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to their New Drug Application (NDA) filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium-223). The application is under review for the treatment of [...]
We all use the Internet to learn about our prostate cancer, your reading this post confirms this statement. The Internet can be a useful tool for finding information and connecting with other patients and caregivers. However, it can also be a nightmare of unreliable misinformation. Understanding what is credible, accurate and reliable information about prostate [...]
One of the most common gripes I hear (and one that I often express) is that Medical news changes often. How often do we hear of a "breakthrough" only to be disputed the next week. It is confusing and it is difficult to know what news to believe and whether we should change a practice, [...]